Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy — Lucile Capuron (2001) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy
Shared by
Michael Maes
University of Electronic Science and Technology of China
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy
Article
2001
en
Authors
+4 more
LC
Lucile Capuron
AR
Alain Ravaud
NG
N. Gualde
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2002
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy
Lucile Capuron
,
Alain Ravaud
,
P.J. Neveu
,
Andrew H. Miller
,
Michael Maes
,
Robert Dantzer
Article
2000
Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms
Michael Maes
,
Ai-hua Lin
,
Willem Ombelet
,
Karolien Stevens
,
Günter Kenis
,
Raf De Jongh
,
John Cox
,
Eugène Bosmans
Article
2001
Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy
Michael Maes
,
Lucile Capuron
,
Alain Ravaud
,
Norbert Gualde
,
Eugene Bosmans
,
Belinda Egyed
,
Robert Dantzer
,
Pierre J. Neveu
Article
2021
Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.
Evangelos Eleutherakis Papaiakovou
,
Efstathios Kastritis
,
Flora Zagouri
,
Dimitra Grapsa
,
Ioannis Ntanassis-Stathopoulos
,
Dimitra Stefanou
,
George Evangelou
,
Ilias Kotteas
,
Meletios A Dimopoulos
,
Konstantinos Syrigos
Article
2010
Photodynamic therapy for cancer and activation of immune response
Paweł Mróz
,
Ying‐Ying Huang
,
Michael R Hamblin
Discussion(0)
No comments yet. Be the first to comment.